Oukessou, Abderrahim
Bristol-Myers Squibb (United States)
2 papers on CoChat
Most cited papers
- Verified
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 1,366
- Verified
First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet
Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies
Cited by 1,215
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free